STOCK TITAN

Revolution Medicines (RVMD) director receives new stock and option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Revolution Medicines director Sandra Horning reported equity compensation awards. She received 1,191 shares of common stock at no cost, bringing her direct holdings to 97,765 shares, which include 6,083 restricted stock units. She was also granted a stock option for 3,127 shares at an exercise price of $162.99 per share, expiring on June 18, 2036.

The option vests in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next Annual Meeting, as long as she continues to serve as a service provider under the company’s 2020 plan.

Positive

  • None.

Negative

  • None.
Insider Horning Sandra
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 3,127 $0.00 --
Grant/Award Common Stock 1,191 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 3,127 shares (Direct); Common Stock — 97,765 shares (Direct)
Footnotes (1)
  1. Includes 6,083 restricted stock units. Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.
Common shares granted 1,191 shares Equity award on June 18, 2026
Stock option grant size 3,127 shares Underlying common stock for new option
Option exercise price $162.99 per share Strike price for new stock option
Option expiration June 18, 2036 New stock option term end date
Total common shares held 97,765 shares Direct holdings after awards, including RSUs
Restricted stock units included 6,083 RSUs Part of total common share figure
restricted stock units financial
"Includes 6,083 restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy financial
"Stock Option (Right to Buy)"
Annual Meeting financial
"immediately prior to the Annual Meeting following the date of grant"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
Service Provider financial
"subject to the Reporting Person remaining a Service Provider"
2020 Plan financial
"as defined in the 2020 Plan through the vesting date"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transactions did RVMD director Sandra Horning report?

Sandra Horning reported equity compensation grants, not open-market trades. She received 1,191 shares of common stock at no cost and a stock option for 3,127 shares, both dated June 18, 2026, increasing her direct ownership stake.

How many Revolution Medicines (RVMD) shares does Sandra Horning now hold?

After the grants, Sandra Horning holds 97,765 shares of common stock directly. This total includes 6,083 restricted stock units that will settle in shares if vesting conditions are met, reflecting her overall equity stake in the company.

What are the terms of Sandra Horning’s new RVMD stock option grant?

She received a stock option for 3,127 shares of common stock at an exercise price of $162.99 per share. The option expires on June 18, 2036 and represents additional potential future ownership if exercised.

When will Sandra Horning’s new RVMD stock option vest?

The stock option will vest in full on the earlier of the first anniversary of June 18, 2026 or immediately before the Annual Meeting after the grant date, provided she remains a service provider under the company’s 2020 equity plan.

Are Sandra Horning’s recent RVMD transactions open-market buys or sales?

The reported transactions are compensation-related awards, not market purchases or sales. She received shares and options at no cash cost, reflecting standard director equity compensation rather than trading based on the company’s share price.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Horning Sandra

(Last)(First)(Middle)
C/O REVOLUTION MEDICINES, INC.
700 SAGINAW DR

(Street)
REDWOOD CITY CALIFORNIA 94063

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/18/2026A1,191A$097,765(1)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$162.9906/18/2026A3,127 (2)06/18/2036Common Stock3,127$03,127D
Explanation of Responses:
1. Includes 6,083 restricted stock units.
2. Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.
/s/ Jack Anders, as Attorney-in-fact for Sandra Horning06/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)